• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Edwards CFO Ullem: Share buybacks more likely than M&A

Edwards CFO Ullem: Share buybacks more likely than M&A

February 4, 2015 By Brian Johnson

Edwards CFO Ullem: Share buybacks more likely than M&A

After a stellar 2014, Edwards Lifesciences (NYSE:EW) has enough cash to be a player in the M&A market, but company officials told analysts today that Edwards isn’t likely to jump into the hot acquisitions market anytime soon.

Scott Ullem, the Irvine, Calif.-based heart valve maker’s
CFO, said Edwards is more likely to initiate a share buyback program than spend its cash on companies.

"We’re active in the area of M&A, but it’s all small investments," Ullem said during a conference call discussing Edwards’ 2014 results.

"It could be intellectual property investments, it could be joint-venture, minority investments," Ullem said. "We have been accumulating cash and we’ve got that cash available for all kinds of purposes, but I expect that we’ll spend more of that on share repurchase than we will on M&A."

Earlier today Edwards said its profits rose 45.4% to $109.2 million, or $1.00 per share, during the 3 months ended Dec. 31, 2014, from $75.1 million, or 68¢ per share, a year earlier. Revenue for the quarter rose 15.3% to $618 million, edging past Wall Street estimates of $611 million.

For the full year, Edwards reported profit growth of 108.5% to $811.1 million, or $7.48 per share, on sales growth of 13.6% to $2.32 billion. Adjusted EPS were $3.50 in 2014, 12¢ ahead of The Street.

Edwards also boosted its cash position by about $230 million and is now carrying more than $650 million in cash and current assetts on its balance sheet, more than enough to pull off a substantial deal.

The company has been relatively quiet on the M&A front over the past year, chosing to do smaller investment deals like its participation in a $50 million funding round for CardioKinetix, which gives Edwards a right to purchase the company based on regulatory milestones. CardioKinetix is currently pursuing U.S. regulatory approval for its Parachute ventricular partitioning device, a treatment for heart failure.


Filed Under: MassDevice Earnings Roundup, Mergers & Acquisitions, News Well, Replacement Heart Valves Tagged With: 2014, CardioKinetix Inc., Edwards Lifesciences, Q4

More recent news

  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure
  • NanoVibronix enters into $50M financing agreement

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy